Rhythm Pharmaceuticals (RYTM) Research & Development (2016 - 2026)
Rhythm Pharmaceuticals (RYTM) posted quarterly Research & Development of $41.7 million for Q1 2026, up 12.85% year-over-year from $37.0 million in Q1 2025, and down 0.73% quarter-over-quarter from $42.0 million in Q4 2025.
Rhythm Pharmaceuticals (RYTM) Research & Development (2016 - 2026) Analysis & Trends
Rhythm Pharmaceuticals (RYTM) has reported Research & Development for 11 consecutive years, with $41.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Research & Development rose 12.85% year-over-year to $41.7 million; the TTM figure through Mar 2026 stood at $172.1 million (up 17.66% YoY), while the FY2025 annual figure was $167.3 million, down 29.68% from the prior year.
- Research & Development retreated to $41.7 million in Q1 2026 per RYTM's latest filing, from $42.0 million in the prior quarter.
- Across five years, Research & Development topped out at $128.7 million in Q1 2024 and bottomed at $21.1 million in Q3 2022.
- Historically, Research & Development has averaged $40.6 million across 5 years, with a median of $37.0 million in 2025.
- Annual changes were most pronounced in 2024 — Research & Development soared 239.08% — and 2025, when it slumped 71.26%.
- Rhythm Pharmaceuticals' Research & Development stood at $23.5 million in 2022, then increased by 26.94% to $29.9 million in 2023, then jumped by 37.72% to $41.2 million in 2024, then grew by 2.1% to $42.0 million in 2025, then declined by 0.73% to $41.7 million in 2026.
- Business Quant data shows RYTM's Research & Development at $41.7 million in Q1 2026, $42.0 million in Q4 2025, and $46.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | Rhythm Pharmaceuticals | 7.95 Bn | 7.62 Bn | 62.32 Mn | 43.43 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 43.43 Mn |
| Mar 31, 2026 | 41.73 Mn |
| Dec 31, 2025 | 42.03 Mn |
| Sep 30, 2025 | 46.03 Mn |
| Jun 30, 2025 | 42.31 Mn |
| Mar 31, 2025 | 36.97 Mn |
| Dec 31, 2024 | 41.17 Mn |
| Sep 30, 2024 | 37.93 Mn |
| Jun 30, 2024 | 30.19 Mn |
| Mar 31, 2024 | 128.67 Mn |
| Dec 31, 2023 | 29.89 Mn |
| Sep 30, 2023 | 33.57 Mn |
| Jun 30, 2023 | 33.54 Mn |
| Mar 31, 2023 | 37.95 Mn |
| Dec 31, 2022 | 23.55 Mn |
| Sep 30, 2022 | 21.12 Mn |
| Jun 30, 2022 | 31.46 Mn |
| Mar 31, 2022 | 32.51 Mn |
| Dec 31, 2021 | 31.57 Mn |
| Sep 30, 2021 | 27.54 Mn |